Literature DB >> 16234329

Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis.

Pavel Krejci1, Bernard Masri, Vincent Fontaine, Pertchoui B Mekikian, Maryann Weis, Herve Prats, William R Wilcox.   

Abstract

Overexpression of C-natriuretic peptide (CNP) in cartilage partially rescues achondroplasia in the mouse. Here, we studied the interaction of fibroblast growth factor (FGF) and CNP signaling in chondrocytes. CNP antagonized FGF2-induced growth arrest of rat chondrosarcoma (RCS) chondrocytes by inhibition of the Erk mitogen activated protein kinase pathway. This effect of CNP was protein kinase G-dependent and was mimicked by the cGMP analog pCPT-cGMP. FGF2-mediated activation of both MEK and Raf-1 but not Ras or FRS2 was abolished by CNP demonstrating that CNP blocks the Erk pathway at the level of Raf-1. CNP also counteracted the FGF2-mediated degradation of RCS extracellular matrix. CNP partially antagonized FGF2-induced expression, release and activation of several matrix-remodeling molecules including matrix metalloproteinase 2 (MMP2), MMP3, MMP9, MMP10 and MMP13. In addition, CNP compensated for FGF2-mediated matrix loss by upregulation of matrix production independent of its interference with FGF signaling. We conclude that CNP utilizes both direct and indirect ways to counteract the effects of FGF signaling in a chondrocyte environment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234329     DOI: 10.1242/jcs.02618

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  69 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 2.  Advances in Skeletal Dysplasia Genetics.

Authors:  Krista A Geister; Sally A Camper
Journal:  Annu Rev Genomics Hum Genet       Date:  2015-04-22       Impact factor: 8.929

3.  Instability restricts signaling of multiple fibroblast growth factors.

Authors:  Marcela Buchtova; Radka Chaloupkova; Malgorzata Zakrzewska; Iva Vesela; Petra Cela; Jana Barathova; Iva Gudernova; Renata Zajickova; Lukas Trantirek; Jorge Martin; Michal Kostas; Jacek Otlewski; Jiri Damborsky; Alois Kozubik; Antoni Wiedlocha; Pavel Krejci
Journal:  Cell Mol Life Sci       Date:  2015-02-18       Impact factor: 9.261

Review 4.  A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation.

Authors:  Elena Kozhemyakina; Andrew B Lassar; Elazar Zelzer
Journal:  Development       Date:  2015-03-01       Impact factor: 6.868

5.  NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.

Authors:  Pavel Krejci; Shunichi Murakami; Jirina Prochazkova; Lukas Trantirek; Katarina Chlebova; Zhufeng Ouyang; Anie Aklian; Jiri Smutny; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

Review 6.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

7.  FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence.

Authors:  Pavel Krejci; Jirina Prochazkova; Jiri Smutny; Katarina Chlebova; Patricia Lin; Anie Aklian; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  Bone       Date:  2010-03-31       Impact factor: 4.398

8.  Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Petra Jelinkova; Katerina Pejchalova; Alois Kozubik; Leslie Michels Thompson; William R Wilcox
Journal:  Cell Signal       Date:  2008-10-12       Impact factor: 4.315

9.  A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type.

Authors:  Krista A Geister; Michelle L Brinkmeier; Minnie Hsieh; Susan M Faust; I Jill Karolyi; Joseph E Perosky; Kenneth M Kozloff; Marco Conti; Sally A Camper
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

10.  Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway.

Authors:  Pavel Krejci; Katerina Pejchalova; William R Wilcox
Journal:  Invest New Drugs       Date:  2007-04-26       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.